Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperdal Consta for Prevention of Mood Episodes in Bipolar 1 Disorder
NCT00132678Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Feb 2005
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder comparing Risperdal Consta with Placebo (2 arms). Primary endpoint: Number of Participants Who Had a Mood Relapse at 24 months. Started Feb 2005; status: completed.
02
Drugs
risperidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00132678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132678.